Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | SIRT2 | Q8IXJ6 | 12/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 12/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.36 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.34 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20831162 | 0.90 | SIRT2 (0.36) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL25413079 | 0.90 | HDAC3 (0.36) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL20830828 | 0.89 | SIRT2 (0.34) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL22698653 | 0.84 | SIRT2 (0.36) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL22698603 | 0.83 | SIRT2 (0.35) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL19683931 | 0.81 | SIRT2 (0.37) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL18332122 | 0.81 | PLG (0.38) | OPRM1OPRD1OPRK1SIRT2SIRT1 | |
| SCHEMBL28953170 | 0.81 | SIRT2 (0.38) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL20831135 | 0.81 | KLKB1 (0.35) | SIRT2SIRT1SIRT3SIRT5 | |
| SCHEMBL17813693 | 0.80 | RAB9A (0.36) | OPRM1OPRD1OPRK1SIRT2SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | OPRM1 2454/4885OPRD1 4739/4885OPRK1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.